IDiyas

For the Inventor, By the Inventor

Newton, MA, United States of America

John Laird Buchanan

USPTO Granted Patents = 12

Average Co-Inventor Count = 8.7

ph-index = 5

Forward Citations = 277(Granted Patents)


Location History:

  • Brookline, MA (US) (2005 - 2008)
  • Newton, MA (US) (2006 - 2016)

Company Filing History:

goldMedal12 out of 1,970 
 
Amgen Inc.
 patents

Years Active: 2005-2016

where 'Filed Patents' based on already Granted Patents

12 patents (USPTO):
1. 9505749 - Quinazolinone compounds and derivatives thereof (2016-11-29),
2. 9340549 - Oxazolidinone compounds and derivatives thereof (2016-05-17),
3. 9334269 - Carboxamides as inhibitors of voltage-gated sodium channels (2016-05-10),
4. 8178557 - Compounds and methods of use (2012-05-15),
5. 7776867 - Furanopyrimidines (2010-08-17),
6. 7763624 - Substituted pyrazolo[3,4-d]pyrimidines as ACK-1 and LCK inhibitors (2010-07-27),
7. 7442698 - Substituted heterocyclic compounds and methods of use (2008-10-28),
8. 7435823 - Compounds and methods of use (2008-10-14),
9. 7115617 - Amino-substituted pyrimidinyl derivatives and methods of use (2006-10-03),
10. 7074789 - Kinase inhibitors (2006-07-11),
11. 6939874 - Substituted pyrimidinyl derivatives and methods of use (2005-09-06),
12. 6881737 - Substituted triazinyl acrylamide derivatives and methods of use (2005-04-19),

Title: Innovations by John Laird Buchanan: Advancements in Quinazolinone and Oxazolidinone Compounds

Introduction: John Laird Buchanan is an accomplished inventor based in Newton, MA, known for his significant contributions to the field of medicinal chemistry. With an impressive portfolio of 12 patents, he has made substantial strides in the development of chemical compounds that serve as inhibitors for various biological targets.

Latest Patents: Among his latest innovations, Buchanan has focused on the creation of quinazolinone compounds and derivatives that are potential inhibitors of tankyrase. The compounds he has developed are characterized by a specific structure defined in his patents. Additionally, he has also worked on oxazolidinone compounds, which similarly exhibit properties useful in inhibiting tankyrase, further expanding the applications of his research.

Career Highlights: John Laird Buchanan is currently employed at Amgen Inc., where he utilizes his expertise to drive forward therapeutic advancements within the company. His research efforts have highlighted the importance of developing targeted therapies to address various health challenges.

Collaborations: Throughout his career, Buchanan has collaborated with notable colleagues such as Perry M. Novak and Xiaotian Zhu. These partnerships have fostered an environment of innovation and have contributed to the success of the projects he has undertaken.

Conclusion: John Laird Buchanan's work in the field of chemistry, particularly with quinazolinone and oxazolidinone compounds, underscores the impact of inventive research on the pharmaceutical landscape. His dedication to innovation at Amgen Inc. continues to pave the way for new therapeutic applications, reflecting the essential role of inventors in advancing science and medicine.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…